Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2

Published 2016 View Full Article

Authors

Keywords

celecoxib, chronic myelogenous leukemia (CML), cyclooxygenase-2 (COX2), AMP-activated kinase (AMPK), beta-catenin (β-catenin), mammalian target of rapamycin (mTOR)

Journal

Oncotarget

Volume 7, Issue 49, Pages -

Publisher

Impact Journals, LLC

Online

2016-11-07

DOI

10.18632/oncotarget.13146

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now